ELAN
Price
$17.94
Change
-$0.06 (-0.33%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
8.92B
88 days until earnings call
TLRY
Price
$1.04
Change
-$0.14 (-11.86%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
1.13B
48 days until earnings call
Interact to see
Advertisement

ELAN vs TLRY

Header iconELAN vs TLRY Comparison
Open Charts ELAN vs TLRYBanner chart's image
Elanco Animal Health
Price$17.94
Change-$0.06 (-0.33%)
Volume$93.46K
Capitalization8.92B
Tilray Brands
Price$1.04
Change-$0.14 (-11.86%)
Volume$606.08K
Capitalization1.13B
ELAN vs TLRY Comparison Chart in %
Loading...
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELAN vs. TLRY commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Hold and TLRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (ELAN: $17.96 vs. TLRY: $1.18)
Brand notoriety: ELAN and TLRY are both notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 125% vs. TLRY: 296%
Market capitalization -- ELAN: $8.92B vs. TLRY: $1.13B
ELAN [@Pharmaceuticals: Generic] is valued at $8.92B. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $1.13B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 0 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • ELAN’s FA Score: 0 green, 5 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, TLRY is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 5 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).

  • ELAN’s TA Score: 5 bullish, 4 bearish.
  • TLRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ELAN is a better buy in the short-term than TLRY.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а +7.74% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was +81.40% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.28%. For the same industry, the average monthly price growth was +69.16%, and the average quarterly price growth was +81.30%.

Reported Earning Dates

ELAN is expected to report earnings on Nov 11, 2025.

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.28% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($8.92B) has a higher market cap than TLRY($1.13B). ELAN YTD gains are higher at: 48.307 vs. TLRY (-11.278). ELAN has higher annual earnings (EBITDA): 1.4B vs. TLRY (-2.13B). ELAN has more cash in the bank: 487M vs. TLRY (256M). TLRY has less debt than ELAN: TLRY (329M) vs ELAN (4.4B). ELAN has higher revenues than TLRY: ELAN (4.43B) vs TLRY (821M).
ELANTLRYELAN / TLRY
Capitalization8.92B1.13B789%
EBITDA1.4B-2.13B-66%
Gain YTD48.307-11.278-428%
P/E Ratio20.41N/A-
Revenue4.43B821M539%
Total Cash487M256M190%
Total Debt4.4B329M1,336%
FUNDAMENTALS RATINGS
ELAN vs TLRY: Fundamental Ratings
ELAN
TLRY
OUTLOOK RATING
1..100
1724
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8198
PRICE GROWTH RATING
1..100
3835
P/E GROWTH RATING
1..100
9394
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (53) in the Biotechnology industry is somewhat better than the same rating for ELAN (93) in the Agricultural Commodities Or Milling industry. This means that TLRY’s stock grew somewhat faster than ELAN’s over the last 12 months.

TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ELAN (100) in the Agricultural Commodities Or Milling industry. This means that TLRY’s stock grew similarly to ELAN’s over the last 12 months.

ELAN's SMR Rating (81) in the Agricultural Commodities Or Milling industry is in the same range as TLRY (98) in the Biotechnology industry. This means that ELAN’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's Price Growth Rating (35) in the Biotechnology industry is in the same range as ELAN (38) in the Agricultural Commodities Or Milling industry. This means that TLRY’s stock grew similarly to ELAN’s over the last 12 months.

ELAN's P/E Growth Rating (93) in the Agricultural Commodities Or Milling industry is in the same range as TLRY (94) in the Biotechnology industry. This means that ELAN’s stock grew similarly to TLRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANTLRY
RSI
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 16 days ago
73%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GPROX16.470.03
+0.18%
Grandeur Peak Global Reach Inv
JWWCX121.64N/A
N/A
Janus Henderson Global Research C
CFCYX14.45N/A
N/A
Columbia Flexible Capital Income Inst3
MBINX31.59-0.04
-0.13%
NYLI Balanced Investor Class
WSHCX64.08-0.14
-0.22%
American Funds Washington Mutual C